Drug Discovery for Schizophrenia
Royal Society of Chemistry (Verlag)
978-1-83767-205-9 (ISBN)
- Noch nicht erschienen (ca. Dezember 2024)
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Following progress in schizophrenia since 2015, this new volume covers the advancing knowledge of scientists and clinicians in drug discovery. The book enhances our understanding of pathological neural communication between the peripheral nervous system (PNS) and central nervous system (CNS) in patients with schizophrenia. Although 75% of neural information passes through the PNS, interactions between the PNS and CNS in schizophrenia remain understudied. Consequently, the current view of schizophrenia requires improvement to facilitate diagnostics and drug development.
In this context, this second volume presents current evidence that views schizophrenia as a mild abnormal maldevelopment of the entire body. This includes impaired functioning of sensory systems (e.g. olfaction), and changes in blood biochemistry and the autonomic nervous system (e.g. vagal body-to-brain communication). Alternative approaches to prevent and treat schizophrenia involve advanced techniques such as opto- and chemo-genetics, as well as local administration of compounds (e.g. intranasally) targeting PNS-based cellular and molecular pathways. Chapters focus on the genetics of schizophrenia, leveraging technological advancements in high-throughput genomics and computational biology. These tools help identify novel therapeutic targets and enable the safe repurposing of existing medications.
The book emphasizes the need to develop new strategies for creating more suitable animal models of schizophrenia, considering the crucial role of the PNS in the disorder’s aetiology. While PNS-based mechanisms are often overlooked, discussing them with caution is essential. Systematically accumulating knowledge about PNS-CNS pathological mechanisms will benefit psychiatric neuroscience, offering fresh perspectives for drug discovery.
Overall, the book synthesizes expert opinions from academia and clinical studies, covering progress in genetics/pharmacogenetics, molecular and cellular neuroscience, neurobiology, pharmacology and animal models.
Genetic Architecture of Schizophrenia: Transitioning from Candidate Genes to Polygenic Risk Scores
Psychotic Illness as a Disorder of Subtle, Whole-body Maldevelopment: Challenges and Opportunities for Drug Discovery
Combinatorial Behavioural Phenotyping of Mouse Models of Schizophrenia
Beyond Brain Boundaries: The Emerging Significance of Vagal Body-to-brain Communication in Schizophrenia
Iron Dyshomeostasis in Schizophrenia and Potential Treatments to Mitigate Its Effects
Smell of Dopamine in Schizophrenia: Towards Drug-discovery
Aromatherapy: A Novel Approach to Schizophrenia Treatment
Emerging Non-invasive Brain Stimulations for Schizophrenia
From Circuits to Drug Targets: The Promise Of Opto- and Chemogenetics for Drug Discovery
Therapeutic Implications of Recent Genomic Discoveries in Schizophrenia
| Erscheint lt. Verlag | 6.12.2024 |
|---|---|
| Reihe/Serie | Drug Discovery ; Volume 84 |
| Verlagsort | Cambridge |
| Sprache | englisch |
| Maße | 156 x 234 mm |
| Gewicht | 551 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
| Naturwissenschaften ► Chemie | |
| ISBN-10 | 1-83767-205-9 / 1837672059 |
| ISBN-13 | 978-1-83767-205-9 / 9781837672059 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
